Repligen 

$114.2
31
+$0.44+0.39% Friday 20:00

Statistics

Day High
116.01
Day Low
112.84
52W High
175.77
52W Low
102.97
Volume
1,099,079
Avg. Volume
749,406
Mkt Cap
6.43B
P/E Ratio
14,906
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.34
0.39
0.44
0.49
Expected EPS
0.386722
Actual EPS
N/A

Financials

6.62%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.48BRevenue
97.79MNet Income

Analyst Ratings

$174.17Average Price Target
The highest estimate is 195.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGEN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Danaher
DHR
Mkt Cap152.13B
Danaher Corporation operates in the life sciences field, offering products and services similar to Repligen's bioprocessing technologies, making them direct competitors in the biotech and pharmaceutical manufacturing sector.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific provides a range of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics, overlapping with Repligen's offerings in bioprocessing and biomanufacturing.
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Bio-Rad Laboratories offers products and services in the field of life science research and clinical diagnostics, competing with Repligen in the supply of bioprocessing equipment and consumables.
Sartorius
SARTF
Mkt Cap17.06B
Sartorius AG competes with Repligen in the bioprocessing market, offering similar bioprocess solutions including filters and single-use systems for the biopharmaceutical industry.
Illumina
ILMN
Mkt Cap18.99B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which, while more focused on genomics, competes with Repligen in the broader biotech research and development space.
Casey`s General Stores
CASY
Mkt Cap19.08B
Catalent, Inc. offers delivery technologies and development solutions for drugs, biologics, and consumer health products, competing with Repligen in the biomanufacturing and bioprocessing sectors.
Avantor
AVTR
Mkt Cap8.06B
Avantor, Inc. provides products and services to the life sciences and advanced technology industries, competing with Repligen in the supply of materials and consumables for bioprocessing.
Repligen
RGEN
Mkt Cap8.39B
Regeneron Pharmaceuticals, while primarily a biotechnology company focused on developing and commercializing pharmaceuticals, competes with Repligen through its demand and innovation in bioprocessing technologies for drug development.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc., as a biopharmaceutical company, indirectly competes with Repligen by developing bioprocessing technologies in-house for their drug development, representing competition for market share in bioprocessing solutions.
GE HealthCare Technologies
GEHC
Mkt Cap34.14B
GE Healthcare provides medical technology and digital solutions, including bioprocessing technologies that compete with Repligen's offerings in the life sciences and biopharmaceutical manufacturing sectors.

About

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Mr. Anthony J. Hunt
Employees
1778
Country
US
ISIN
US7599161095

Listings

0 Comments

Share your thoughts

FAQ

What is Repligen stock price today?
The current price of RGEN is $114.2 USD — it has increased by +0.39% in the past 24 hours. Watch Repligen stock price performance more closely on the chart.
What is Repligen stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Repligen stocks are traded under the ticker RGEN.
Is Repligen stock price growing?
RGEN stock has fallen by -4.83% compared to the previous week, the month change is a -16.3% fall, over the last year Repligen has showed a -24.16% decrease.
What is Repligen market cap?
Today Repligen has the market capitalization of 6.43B
When is the next Repligen earnings date?
Repligen is going to release the next earnings report on May 05, 2026.
What were Repligen earnings last quarter?
RGEN earnings for the last quarter are 0.49 USD per share, whereas the estimation was 0.44 USD resulting in a +11.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Repligen revenue for the last year?
Repligen revenue for the last year amounts to 1.48B USD.
What is Repligen net income for the last year?
RGEN net income for the last year is 97.79M USD.
How many employees does Repligen have?
As of March 15, 2026, the company has 1,778 employees.
In which sector is Repligen located?
Repligen operates in the Health Care sector.
When did Repligen complete a stock split?
Repligen has not had any recent stock splits.
Where is Repligen headquartered?
Repligen is headquartered in Waltham, US.